What does Catheter Precision do today?
Catheter Precision, Inc. trades on NYSE American as VTAK and now combines cardiac electrophysiology products with private aviation services. Its medical portfolio includes VIVO, a non-invasive three-dimensional mapping system for ventricular arrhythmias, and LockeT, a post-procedure suture-retention device. In March 2026, the company added FLYTE and Ponderosa Air, creating a second segment offering short-haul air-taxi flights and charter brokerage. The result is an unusually diverse microcap that must be analyzed by segment.
Two businesses now sit under one ticker
The cardiac business remains the source of the corporate identity described on the official company website. VIVO combines CT or MRI anatomy, a standard 12-lead ECG and proprietary algorithms to create a patient-specific activation map before an ablation procedure. LockeT is simpler: it retains a figure-of-eight suture at the vascular access site, allowing the clinician to monitor and release pressure without leaving a permanent implant. The aviation segment is operationally different. Hops acts as principal on short-haul flights, while Luxe generally acts as an agent arranging travel through third-party operators.
| Business | Offering | Customer | Economic character |
|---|---|---|---|
| VIVO | Pre-procedure ventricular-arrhythmia localization | Electrophysiology labs and physicians | System, software and procedure-related product revenue |
| LockeT | Single-use suture-retention device | Hospitals and catheter laboratories | Consumable product sales through direct and distributor channels |
| FLYTE Hops | Short-haul private flights | Regional private-air travelers | Gross flight revenue recognized when service is completed |
| FLYTE Luxe | Charter brokerage | Travelers requiring broader aircraft access | Net commission revenue because FLYTE acts as agent |
How does Catheter Precision make money?
VTAK has four revenue streams with different recognition and capital needs. LockeT generates repeat consumable demand, while VIVO adds system, software and procedure-related sales. Hops records the full customer charge because FLYTE controls the flight service; Luxe records only its brokerage commission because it acts as agent. Equal customer spending can therefore produce very different reported revenue.
Which revenue stream mattered most in Q1 2026?
Why the revenue mix is strategically important
The medical business has attractive reported product gross margins but limited commercial scale. Aviation can expand the top line faster, yet Hops carries aircraft, pilot, fuel, maintenance and scheduling exposure. Luxe is less asset-intensive, but net commission accounting makes its revenue look smaller. For analysis, revenue growth should therefore be separated into medical unit adoption, Hops flight activity and Luxe brokerage economics rather than treated as one homogeneous trend.
What does the latest quarter show?
The Form 10-Q for the quarter ended March 31, 2026 shows fast growth from a small base. Revenue rose to $432K from $143K, about 202%. Medical products contributed $248K and aviation added $184K. Gross profit was $390K, but $2.708M of operating expenses still overwhelmed it.
Growth improved, but fixed costs still dominate
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $432K | $143K | Acquisition contribution plus higher VIVO and LockeT sales |
| Gross profit | $390K | $126K | High reported margin, though absolute dollars remain small |
| SG&A | $2.559M | $3.485M | Lower year over year, but nearly six times quarterly revenue |
| Operating loss | $(2.318M) | $(3.575M) | Narrowed, yet the business remained far from break-even |
| Diluted loss per share | $(1.39) | $(6.81) | Share count and capital transactions complicate period comparisons |
Why the 90.3% gross margin can mislead
Geographically, $278K of Q1 revenue came from the United States and $154K came from Europe, equal to 64.4% and 35.6% of the total. Three customers represented 17%, 15% and 12% of accounts receivable at quarter-end. That concentration matters because a delayed hospital, distributor or travel payment can materially affect a company with only $441K of quarter-end cash.
Which turning points reshaped VTAK?
VTAK is the product of repeated pivots rather than linear expansion. The 2025 Form 10-K explains the shift from laser technology to electrophysiology, while 2026 filings document the move into aviation. Each transition changed the market opportunity, financing need and risk profile.
-
2002The predecessor was incorporated in California around an excimer-laser platform. This history explains why the public entity accumulated substantial deficits before the present product set emerged.
-
2018The company reincorporated in Delaware and entered the public-market structure used today.
-
January 2023A merger with the former Catheter Precision shifted the operating focus to cardiac electrophysiology and brought VIVO and LockeT into the listed company.
-
May 2024LockeT recorded its first commercial sale, establishing a repeat-use consumable revenue stream.
-
2025The company created Cardionomix and KardioNav, transferred or acquired medical-device assets, obtained a LockeT patent and CE Mark, and executed a 1-for-19 reverse stock split.
-
December 2025LockeT royalty rights were exchanged for 9,489.488 Series J preferred shares, simplifying one liability while creating substantial potential common-stock conversion.
-
March 2026VTAK completed its purchase of FLYTE and Ponderosa Air, recognized $9.7M of goodwill and became a two-segment medtech-and-aviation company.
-
June 2026The company agreed to invest $1.0M in Volato securities, extending capital allocation further into the aviation ecosystem.
The 2023 merger created the medical-device thesis
VIVO had already built a clinical history before the public-company combination. The official VIVO product page describes a system that uses patient-specific anatomy and ECG inputs to localize ventricular onset. The company reports more than 1,000 procedures and cites 99.5% localization accuracy, while its filings discuss a 51-patient U.S. study and a 125-patient European registry. These data create commercial credibility, but adoption remains the decisive test because clinical validation has not yet translated into large revenue.
The 2026 aviation pivot changed the risk equation
The FLYTE transaction added revenue immediately, but it also introduced leases, aircraft operations, pilot availability, fuel exposure, insurance, regulatory oversight and third-party operator dependence. It created $9.7M of goodwill and included a $5.0M zero-interest promissory note payable through December 2026. That combination makes acquisition integration and financing capacity central to the analysis. The June 2026 Volato investment agreement reinforces management’s willingness to deploy scarce capital into aviation-related opportunities.
What gives Catheter Precision a competitive edge—and what does not?
VTAK has differentiated assets, but it does not yet possess the scale-based moat of a mature medical-device manufacturer or a large charter network. Its strongest resources are product-specific: proprietary VIVO algorithms, regulatory clearances, clinical evidence, a growing installed-use history and LockeT’s simple consumable workflow. The official LockeT page highlights use with catheter sizes up to 27F and reports hemostasis at two hours in 98% of patients. Those are concrete value propositions for labs seeking same-day discharge and manageable access-site closure.
Medical-device differentiation versus incumbent power
| Competitive field | Named competitors in company filings | VTAK position | Main constraint |
|---|---|---|---|
| Electrophysiology systems | Medtronic, Abbott, Biosense Webster and Boston Scientific | Specialized non-invasive localization before ablation | Rivals have larger sales forces, bundled product portfolios and R&D budgets |
| Access-site closure | Abbott Perclose, Haemonetics VASCADE and Inari FlowStasis | Simple external suture-retention approach | Hospital purchasing relationships and established alternatives |
| Private aviation | Charter brokers, membership programs and regional operators | Technology-enabled regional Hops plus asset-light Luxe brokerage | Intense competition, capacity access, customer acquisition and service reliability |
Why distribution may matter more than technology
Larger medtech companies can spend more time with hospitals, bundle products and offer discounts. VTAK must therefore create repeat ordering, distributor productivity and clinician habit, not merely prove that its devices work. Aviation customers similarly judge availability, reliability, safety and price. The company has emerging product differentiation, not entrenched market dominance.
How financially strong is Catheter Precision?
The central financial issue is liquidity, not gross margin. At March 31, 2026, VTAK reported $35.085M of assets and $25.928M of liabilities, but current liabilities were $19.738M and cash was only $441K. The company used $2.796M of cash in operations during Q1. By May 8, 2026, cash had increased to about $1.1M, yet management still stated that available funds were insufficient and that substantial doubt existed about the ability to continue as a going concern for the following twelve months.
Annual losses provide the proper baseline
For fiscal 2025, revenue was $819K, up 95% from $420K. Gross profit was $756K, but operating expenses reached $21.899M, including $6.995M of intangible impairment and $1.967M of acquired in-process R&D. The operating loss was $21.143M, attributable net loss was $17.183M and operating cash outflow was $8.296M. Year-end cash was $88K and the accumulated deficit was $309.535M. High product margin is not financial strength without scale and cash conversion.
Financing, preferred stock and acquisition obligations
| Capital item | Amount or shares | Period | Analytical implication |
|---|---|---|---|
| Cash | $441K | March 31, 2026 | Small cushion relative to operating burn and near-term obligations |
| FLYTE acquisition note | $5.0M principal | Payable through December 15, 2026 | Creates a concentrated short-term funding requirement |
| Series C-2 financing | $3.470M gross; about $3.2M net | April 21, 2026 | Adds liquidity but increases conversion and dilution complexity |
| Goodwill from FLYTE | $9.7M | Q1 2026 acquisition accounting | Future impairment risk if aviation forecasts underperform |
| Total equity | $9.157M | March 31, 2026 | Positive book equity does not eliminate the liquidity deficit |
Who controls the economic story?
Governance reflects a small board, executive influence and a complex related-party capital structure detailed in the 2025 Form 10-K amendment. The leadership page identifies David Jenkins as CEO and Phil Anderson as CFO. Jenkins is also executive chairman and is connected to entities holding preferred shares, notes and warrants, making independent review and stockholder approvals especially important.
Related-party instruments can create substantial voting and dilution effects
| Holder or instrument | Officially disclosed amount | Approval or timing | Why it matters |
|---|---|---|---|
| Common stock | 2,692,473 shares outstanding | March 31, 2026 | Base denominator before preferred conversion and warrants |
| Series J preferred held by Jenkins and FatBoy affiliates | 9,489.488 preferred shares; potential 6,083,005 common shares | Conversion subject to required approvals | Potential common exposure exceeds the quarter-end common share count |
| Series C-1 preferred | 3,470 shares outstanding | March 31, 2026 | Adds another convertible layer to fully diluted analysis |
| Related-party note principal | $1.5M across disclosed notes | Maturities in 2028 and 2029 | Links creditor relationships with insiders and affiliates |
| Board structure | 4 directors; 3 independent | 2026 reporting | Independent committees provide oversight within a compact board |
What governance safeguards exist?
The audit, compensation and nominating committees are composed of independent directors, and the board has three independent members out of four. The company also uses stockholder votes for transactions that require exchange-rule approval. The 2026 definitive proxy materials are therefore essential reading for understanding authorization limits, preferred-stock issuances and reverse-split proposals. For researchers, the practical governance question is whether independent review can balance speed in financing and acquisitions against dilution, related-party exposure and execution risk.
Which KPIs matter most for this hybrid company?
A blended revenue number cannot explain VTAK. Medical performance depends on adoption, repeat consumable demand, geographic expansion and selling efficiency. Aviation requires flight volume, repeat bookings, commission economics and contribution margin. Corporate analysis adds cash burn, working capital, dilution and acquisition obligations.
Medical-device KPIs
| KPI | Current anchor | How to interpret it |
|---|---|---|
| LockeT revenue | $175K in Q1 2026 | Repeat growth would indicate procedure adoption rather than one-time stocking |
| VIVO revenue | $73K in Q1 2026 | Shows whether clinical evidence is converting into system and software demand |
| International mix | $154K Europe revenue in Q1 2026 | Measures distributor reach and the benefit of CE-marked products |
| Product gross margin | High consolidated margin, 90.3% in Q1 2026 | Useful only when paired with selling costs and absolute gross-profit dollars |
Aviation and corporate KPIs
What opportunities and risks follow the FLYTE pivot?
The acquisition creates a path to a larger revenue base but multiplies execution demands. Medical upside requires VIVO and LockeT to win repeat hospital demand. Aviation upside depends on route density, retention, fleet availability and brokerage scale. Diversification is the opportunity; competition for scarce cash and management attention is the danger.
Which risks could change the outlook?
| Risk | Current evidence | Financial line affected | What to monitor |
|---|---|---|---|
| Going-concern and financing risk | $441K cash and $2.796M Q1 operating cash use | Cash, interest, preferred equity and share count | New capital terms and monthly liquidity |
| Acquisition integration | Two unrelated segments combined in March 2026 | SG&A, segment loss and goodwill | FLYTE contribution margin and impairment indicators |
| Aviation regulation and safety | FAA, DOT, TSA, licensing and airworthiness exposure | Revenue interruption, insurance and compliance cost | Permit status, incidents and insurance availability |
| Pilot, fuel and operator costs | Labor constraints and third-party capacity dependence | Service gross margin and customer pricing | Utilization, cancellations and cost pass-through |
| Medical competition | Large incumbents can bundle products and outspend VTAK | Sales growth and selling expense | Repeat orders, new hospitals and distributor output |
| Dilution and control | Multiple preferred series, warrants and related-party instruments | Per-share ownership and voting influence | Stockholder approvals and conversion activity |
The company’s June 2026 Form S-1 is particularly relevant because it shows how financing and resale registration can interact with the operating plan. For a microcap with negative free cash flow, access to capital is not a peripheral risk; it is part of the business model.
Why is VTAK unusually difficult to value?
A conventional DCF needs a stable starting point for revenue, margins and reinvestment. VTAK does not yet provide one: Q1 2026 included only 22 days of FLYTE, medical operations remain subscale, the company carries a going-concern warning, and several preferred series and warrants complicate the share count. Basic-share valuation can differ materially from a fully diluted, financing-adjusted analysis.
The valuation model should be built by segment
What should researchers monitor next?
- A full quarter of FLYTE revenue, gross profit and segment loss, rather than the 22-day Q1 contribution.
- LockeT repeat orders and VIVO system or procedure growth by geography.
- Cash after the April preferred financing and the timing of the $5.0M FLYTE acquisition note.
- SG&A relative to gross profit, because cost reduction must continue as revenue scales.
- Goodwill and intangible-asset impairment indicators after the $9.7M aviation goodwill addition.
- Stockholder approvals, preferred conversions, warrants and the resulting fully diluted share count.
- Aviation repeat bookings, cancellations, pilot availability, fuel costs and third-party operator capacity.
- Any additional strategic investments following the $1.0M Volato transaction.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.